Novartis AG (NVS)
| Market Cap | 237.13B |
| Revenue (ttm) | 56.37B |
| Net Income (ttm) | 14.39B |
| Shares Out | 1.92B |
| EPS (ttm) | 7.30 |
| PE Ratio | 16.48 |
| Forward PE | 14.17 |
| Dividend | $2.60 (2.10%) |
| Ex-Dividend Date | Mar 12, 2025 |
| Volume | 1,655,475 |
| Open | 123.41 |
| Previous Close | 122.61 |
| Day's Range | 122.57 - 124.15 |
| 52-Week Range | 96.06 - 133.55 |
| Beta | 0.57 |
| Analysts | Hold |
| Price Target | 119.00 (-3.87%) |
| Earnings Date | Oct 28, 2025 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $119.0, which is a decrease of -3.87% from the latest price.
News
Novartis AG (NVS) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies Transcript
Novartis AG ( NVS) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies October 30, 2025 11:30 AM EDT Company Participants Isabella Zinck Shreeram Aradhye - President of Develop...
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren's disease Phase III trials
Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren's disease, the second most prevalent rheumatic autoimmune disease2, at a late-breaker presentation during the American ...
3 Investable Laggards In An Overbought Market
The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revo...
Novartis AG (NVS) Q3 2025 Earnings Call Transcript
Novartis AG (NYSE:NVS) Q3 2025 Earnings Call October 28, 2025 9:00 AM EDT Company Participants Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirs...
Novartis completes acquisition of Tourmaline Bio
Basel, October 28, 2025 - Novartis today announced that it has successfully completed its acquisition of Tourmaline Bio, Inc. (“Tourmaline”). With the completion of the acquisition, shares of common s...
Novartis CEO: We're never done with M&A
Vas Narasimhan, CEO of pharmaceuticals company, Novartis, discusses the company's latest $12 billion acquisition of Avidity Biosciences, and ongoing negotiations with the U.S. administration over pote...
Novartis shares fall as profit lags estimates; downside from Entresto patent loss to continue
Shares in Swiss drugmaker Novartis were seen down 3.3% in pre-market trade on Tuesday after the company reported third-quarter profitability below market expectations, even as higher sales from key me...
Novartis posts Q3 income beat, reaffirms FY2025 guidance
Swiss pharma giant Novartis sees Q3 income up by a quarter, allowing it to achieve its FY guidance and countering the fall in generic drug sales Stateside. BNP maintains its forecasts despite Q3 net i...
Novartis looking to add more medicines to direct to patient platform, CEO says
Swiss drugmaker Novartis is exploring options to add more medicines to its direct to patient platform that is expected to launch in the U.S. next month, CEO Vas Narasimhan told Reuters in an interview...
Novartis CEO says pharma giant has the firepower for big M&A deals: 'Can never be done'
The Swiss drugmaker announced its biggest deal in a decade on Sunday, as its set to buy Avidity Biosciences for about $12 billion. "We have adequate firepower to do deals like this and to bolster the...
Novartis Posts Higher Net Profit as Key Drugs Lift Sales
The drugmaker reported third-quarter profit of $3.93 billion after higher sales for key drugs allowed it to offset a hit from patent expirations.
Novartis announces expiration of Tourmaline Bio tender offer
Basel, October 28 2025 - Novartis today announced that its previously announced tender offer (the “offer”) by Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of ...
Novartis Q3 operating income up 6% on new drug sales
Swiss drugmaker Novartis , on a deal-making spree this year, reported a gain in operating income of 6% as growth of its new drugs made up for stagnant revenue from established heart drug Entresto.
Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance
Q3 net sales grew +7% (cc1, +8% USD) and core operating income1 grew +7% (cc, +6% USD). Sales growth was driven by continued strong execution on priority brands including Kisqali (+68% cc), Kesimpta (...
Avidity Biosciences Soars After $72 Per Share Novartis Takeover
Avidity Biosciences, Inc. (NASDAQ:RNA) stock surged after announcing a $12 billion all-cash acquisition by Novartis AG (NYSE:NVS), marking one of the largest biotech buyouts of the year.
Novartis AG (NVS) M&A Call Transcript
Novartis AG (NYSE:NVS) M&A Call October 27, 2025 8:00 AM EDT Company Participants Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Fi...
Trump's trade deals, Novartis acquires Avidity, Taco Bell's beverage push and more in Morning Squawk
President Donald Trump penned several trade agreements ahead of his expected meeting with China leader Xi Jinping later this week. Novartis announced it will buy Avidity Biosciences.
Wall Street Breakfast Podcast: Novartis Puts $12B On The Table
Avidity Biosciences (RNA) surges 42% premarket after Novartis agrees to acquire the company for $12 billion, paying $72 per share in cash. The RNA deal signals renewed Big Pharma interest in RNA thera...
Novartis shares slip, Avidity soars after $12 billion biotech deal
Shares of Novartis fell 1% on Monday following news of the company's plans to acquire U.S. biotech Avidity Biosciences for about $12 billion, marking the Swiss drugmaker's largest acquisition under CE...
Novartis Agrees $12 Billion Biotech Deal for Avidity
Novartis agreed to buy biotechnology company Avidity in a deal valued at $12 billion, making it the Swiss drugmaker's biggest acquisition in more than a decade and adding several potential blockbuster...
Novartis Agrees to Acquire Avidity Biosciences for $12 Billion
The Swiss pharmaceutical company says the purchase would complement its existing pipeline of treatments for neuromuscle disorders.
Novartis to acquire Avidity Biosciences for about $12B
Novartis has been proactively striking deals this year to address the impending patent cliff for some of its blockbuster drugs, including Entresto for heart failure, Xolair for asthma and Cosentyx for...
Novartis Deal Values Avidity Biosciences At $12 Billion
The acquisition would raise the 2024-2029 expected sales compound annual growth rate for Novartis to 6% from 5%, it said.
Novartis to acquire Avidity Biosciences for $12 billion
Swiss drugmaker Novartis on Sunday said it agreed to acquire Avidity Biosciences for $12 billion.
Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG
Novartis to acquire Avidity for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion Avidity expects to separate its early-stage precision cardiology programs into a n...